Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00065442 · MORE INFO

Limitations, agreements, and source contact

Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy · Source last updated 2010-09-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
A provision provides for sponsor review up to 45 days with the right to request modification based on disclosure of confidential information; extendable by 60 days to file a patent application.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
kpicha@dendreon.com
organization
Dendreon Corporation
phone
206-274-6762
title
Kathleen Picha
Complete source fields
certain Agreement
other Details
A provision provides for sponsor review up to 45 days with the right to request modification based on disclosure of confidential information; extendable by 60 days to file a patent application.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
kpicha@dendreon.com
organization
Dendreon Corporation
phone
206-274-6762
title
Kathleen Picha

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice